The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, a forum intended to deepen regulatory understanding and give developers practical support in one of the fastest-growing parts of UK medtech.
The announcement, published on the regulator's official blog, sets out a coordinated effort to help innovators navigate regulatory expectations, improve compliance and bring safe, effective digital mental health products into clinical use. The agency describes the initiative as a response to mounting demand for clarity on evidence requirements, post-market responsibilities and the regulatory landscape for software-based and AI-enabled mental health tools.
A forum spanning the sector
The community is to bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a shared understanding of best practice. Its scope covers technologies ranging from therapeutic apps to AI-supported assessment tools.
Four objectives are set out:
- helping developers interpret regulatory requirements and build compliance into product design at an earlier stage;
- identifying the challenges innovators commonly face, with particular attention to small and medium-sized enterprises entering the mental health space;
- sharing real-world experience from organisations already working through regulatory pathways;
- strengthening dialogue between industry and regulators so that emerging technologies meet expectations on safety, performance and evidence.
The announcement presents the forum as a route for the wider medtech development community to engage directly with the regulator on questions that often decide whether a promising technology reaches patients.
Survey to set initial priorities
To decide where the community starts, the MHRA has opened a survey for digital mental health developers and other stakeholders. It asks about current regulatory difficulties, the areas where clearer guidance would help and ways to improve compliance support.
The agency says it wants broad participation so that the community reflects real-world needs rather than top-down assumptions. For developers, the survey is described as a direct channel for influencing the support that follows and for helping to create a more predictable, transparent environment for innovation.
Developers are encouraged to complete the survey and circulate it within their organisations. The MHRA links a strong response to the community's ability to deliver practical, meaningful support, and by extension to the pace at which safe and effective tools reach patients.